We are monitoring the impact of COVID-19 on Europe Ovarian Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1393
Share on
Share on

Europe Ovarian Cancer Therapeutics Market Research Report – Segmented By Stage Of Cancer, Cancer Type, Diagnosis, Type Of Treatment & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1393
Pages: 181

Europe Ovarian Cancer Therapeutics Market Size (2021 to 2026)

The size of the Europe Ovarian Cancer Therapeutics Market is estimated to hike at a notable CAGR during the forecast period.

The increasing incidence of ovarian cancer drives the market. In addition, the need for more effective treatment options is pushing the growth of the market. Ovarian cancer is the eighth most commonly occurring cancer in women; hence, the growing geriatric population among women in European countries is expected to augment market growth. Aside from that, rising acceptance of new medicines and a robust development pipeline are expected to boost the European ovarian cancer therapeutics market. An increase in new ovarian cancer cases, the ease of use of new medications and therapies, and increased healthcare spending are driving the ovarian cancer medicines market during the forecast period. 

Epithelial ovarian cancer (EOC), which develops from the ovary's epithelium, is the most prevalent kind of ovarian cancer. Ovarian cancer is one of the most common cancers in women in the Europe region. It kills more women than any other cancer of the female genital system, and it ranks fifth in overall cancer deaths among women. Unfortunately, this type of cancer is rarely diagnosed early, making treatment at a complicated stage difficult. 

Additionally, increasing investment and funding by the government and non-government organizations and technological advancements in the healthcare sector in the developed countries such as Germany, UK, Italy, Spain, and France are accelerating the market growth. 

Generics like paclitaxel and carboplatin dominate the market, although medicines like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to enhance revenue. However, the market may face a challenge in the development of more effective medicines. As a result, discovering new medicines to treat this form of cancer is expected to present substantial market potential.

In the pharmaceutical industry, firms are actively inventing and creating combination medicines to treat ovarian cancer. Combination medicines address complicated medical problems by combining two or more active pharmaceutical ingredients (APIs) into a single dose form.

However, the lack of appropriate technology for early detection of ovarian cancer is a key problem impeding the growth of the European ovarian cancer treatments market. Also, the development of medicine with improved efficacy could pose a challenge for market growth.

This research report on the European ovarian cancer therapeutics market has been segmented and sub-segmented into the following categories:

By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The European ovarian cancer therapeutic market is expected to account for a significant share globally during the forecast period. The factors such as the increasing geriatric population, availability of advanced technology in the healthcare sector, and proliferation of ovarian cancer cases propelling the market growth. In addition, some popular medications' patent expiration may also help drive the market further by encouraging new entrants. During the projected period, these shifting dynamics are expected to increase the ovarian cancer market. In addition, the Major pharmaceutical companies in the region are investing in research and development activities that are expected to boost the market growth.

Germany, United Kingdom, Spain, and France are regarded as promising countries with considerable market potential. Ovarian cancer is becoming more common, and it is expected to impact market growth positively. In addition, favorable medical care reforms, increased health awareness, a low-cost basis, and a lack of legal and cultural barriers contribute to the market growth in developed nations are over the forecast period.

In Europe, the United Kingdom has a significant proportion of the ovarian cancer diagnostics and treatments market share. Ovarian cancer is the most common cancer in women in the United Kingdom. Favorable reimbursement policies, advancing the healthcare sector, and infrastructure facilities are most likely to accelerate the market growth in the U.K.

KEY MARKET PLAYERS:

Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.       

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Stage Of Cancer                        

                                5.1.1 Stage I       

                                                5.1.1.1 Stage IA

                                                5.1.1.2 Stage IB

                                                5.1.1.3 Stage IC

                                5.1.2 Stage II     

                                                5.1.2.1 Stage IIA

                                                5.1.2.2 Stage IIB

                                                5.1.2.3 Stage IIC

                                5.1.3 Stage III    

                                                5.1.3.1 Stage IIIA

                                                5.1.3.2 Stage IIIB

                                                5.1.3.3 Stage IIIC

                                5.1.4 Stage IV    

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer               

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Primary Peritoneal Carcinoma        

                                5.2.3 Ovarian Stromal Tumors   

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type      

                                5.2.7 Market Attractiveness Analysis, By Type     

                                5.2.8 Market Share Analysis, By Type      

                5.3 Diagnosis                     

                                5.3.1 Introduction           

                                5.3.2 Physical Examination          

                                5.3.3 Blood Tests             

                                5.3.4 Ultrasound             

                                5.3.5 PET             

                                5.3.6 CT Scan     

                                5.3.7 MRI            

                                5.3.8 Human Chorionic Gonadotropin Test          

                                5.3.9 Biopsy       

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis          

                                5.3.11 Market Attractiveness Analysis, By Diagnosis         

                                5.3.12 Market Share Analysis, By Diagnosis          

                5.4 Treatment                  

                                5.4.1 Introduction           

                                5.4.2 Chemotherapy     

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy              

                                5.4.5 Surgery    

                                5.4.6 Immunotherapy   

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment          

                                5.4.9 Market Attractiveness Analysis, By Treatment         

                                5.4.10 Market Share Analysis, By Treatment       

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Aetera Zenteris Inc.                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Eli Lilly and Company                             

                8.3 Roche                           

                8.4 Amgen                         

                8.5 Janssen Pharmaceuticals, Inc.                             

                8.6 Bristol Myers Squibb Company                          

                8.7 Novogen, Inc.                            

                8.8 GlaxoSmithKline                      

                8.9 Boehringer Ingelheim                            

                8.10 AstraZeneca                            

                8.11 Genentech Inc.                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  2. Europe Stage I Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Stage II Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Stage III Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Stage IV Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  7. Europe Primary Peritoneal Carcinoma Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Ovarian Stromal Tumors Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Ovarian Germ Cell Tumors Market, By Region, From 2021 to 2026 (USD Billion)
  10. Europe Epithelial Ovarian Tumors Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  12. Europe Physical Examination Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Blood Tests Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe Ultrasound Market, By Region, From 2021 to 2026 (USD Billion)
  15. Europe PET Market, By Region, From 2021 to 2026 (USD Billion)
  16. Europe CT Scan Market, By Region, From 2021 to 2026 (USD Billion)
  17. Europe MRI Market, By Region, From 2021 to 2026 (USD Billion)
  18. Europe Human Chorionic Gonadotropin Test Market, By Region, From 2021 to 2026 (USD Billion)
  19. Europe Biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  20. Europe Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  21. Europe Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  22. Europe Radiation Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  23. Europe Hormonal Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  24. Europe Surgery Market, By Region, From 2021 to 2026 (USD Billion)
  25. Europe Immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  26. Europe Targeted Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  27. U.K. Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  28. U.K. Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  29. U.K. Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  30. U.K. Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  31. Germany Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  32. Germany Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  33. Germany Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  34. Germany Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  35. France Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  36. France Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  37. France Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  38. France Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  39. Italy Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  40. Italy Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  41. Italy Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  42. Italy Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  43. Spain Ovarian Cancer Therapeutics Market, By Stage Of Cancer, From 2021 to 2026 (USD Billion)
  44. Spain Ovarian Cancer Therapeutics Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  45. Spain Ovarian Cancer Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  46. Spain Ovarian Cancer Therapeutics Market, By Type Of Treatment, From 2021 to 2026 (USD Billion)
  47. Europe Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  48. Europe Stage IA Market, By Region, From 2021 to 2026 (USD Billion)
  49. Europe Stage IB Market, By Region, From 2021 to 2026 (USD Billion)
  50. Europe Stage IC Market, By Region, From 2021 to 2026 (USD Billion)
  51. U.K. Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  52. Germany Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  53. France Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  54. Italy Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  55. Spain Blood Glucose Monitoring Market, By Stage I, From 2021 to 2026 (USD Billion)
  56. Europe Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  57. Europe Stage IIA Market, By Region, From 2021 to 2026 (USD Billion)
  58. Europe Stage IIB Market, By Region, From 2021 to 2026 (USD Billion)
  59. Europe Stage IIC Market, By Region, From 2021 to 2026 (USD Billion)
  60. U.K. Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  61. Germany Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  62. France Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  63. Italy Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  64. Spain Blood Glucose Monitoring Market, By Stage II, From 2021 to 2026 (USD Billion)
  65. Europe Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  66. Europe Stage IIIA Market, By Region, From 2021 to 2026 (USD Billion)
  67. Europe Stage IIIB Market, By Region, From 2021 to 2026 (USD Billion)
  68. Europe Stage IIIC Market, By Region, From 2021 to 2026 (USD Billion)
  69. U.K. Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  70. Germany Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  71. France Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  72. Italy Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)
  73. Spain Blood Glucose Monitoring Market, By Stage III, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample